Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 7, Pages e1438111
Publisher
Informa UK Limited
Online
2018-02-13
DOI
10.1080/2162402x.2018.1438111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical applications of PD-L1 bioassays for cancer immunotherapy
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- PD-1 checkpoint inhibition: Toxicities and management
- (2017) Andrew W. Hahn et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
- (2016) Archana Anantharaman et al. BMC CANCER
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
- (2016) Omar Abdel-Rahman CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-1/PD-L1 blockade in renal cell cancer
- (2016) Kathryn E. Beckermann et al. Expert Review of Clinical Immunology
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Efficacy of PD-1 blockade in tumors with MMR deficiency
- (2016) Valerie Lee et al. Immunotherapy
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- CTC immune escape mediated by PD-L1
- (2016) Xuefei Wang et al. MEDICAL HYPOTHESES
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
- (2016) C. Alix-Panabieres et al. Cancer Discovery
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment
- (2016) B. L. Khoo et al. Science Advances
- Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
- (2016) Arun Satelli et al. Scientific Reports
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Interferon-γ and tumor necrosis factor-α promote the ability of human placenta–derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4+interleukin-10+ and CD8+interleukin-10+Treg subsets
- (2015) Heng Li et al. CYTOTHERAPY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
- (2015) Abhisek Swaika et al. MOLECULAR IMMUNOLOGY
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
- (2015) Joao Paulo Oliveira-Costa et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Peptide-based isolation of circulating tumor cells by magnetic nanoparticles
- (2014) Linling Bai et al. Journal of Materials Chemistry B
- Evolution of end points for cancer immunotherapy trials
- (2012) A. Hoos ANNALS OF ONCOLOGY
- Circulating Tumor Cells and Circulating Tumor DNA
- (2011) Catherine Alix-Panabières et al. Annual Review of Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now